Literature DB >> 21248239

Neuronal FLT1 receptor and its selective ligand VEGF-B protect against retrograde degeneration of sensory neurons.

Joke Dhondt1, Eve Peeraer, An Verheyen, Rony Nuydens, Ian Buysschaert, Koen Poesen, Katie Van Geyte, Manu Beerens, Masabumi Shibuya, Jody J Haigh, Theo Meert, Peter Carmeliet, Diether Lambrechts.   

Abstract

Even though VEGF-B is a homologue of the potent angiogenic factor VEGF, its angiogenic activities have been controversial. Intrigued by findings that VEGF-B may also affect neuronal cells, we assessed the neuroprotective and vasculoprotective effects of VEGF-B in the skin, in which vessels and nerves are functionally intertwined. Although VEGF-B and its FLT1 receptor were prominently expressed in dorsal root ganglion (DRG) neurons innervating the hindlimb skin, they were not essential for nerve function or vascularization of the skin. However, primary DRG cultures lacking VEGF-B or FLT1 exhibited increased neuronal stress and were more susceptible to paclitaxel-induced cell death. Concomitantly, mice lacking VEGF-B or a functional FLT1 developed more retrograde degeneration of sensory neurons in a model of distal neuropathy. On the other hand, the addition of the VEGF-B isoform, VEGF-B(186), to DRG cultures antagonized neuronal stress, maintained the mitochondrial membrane potential and stimulated neuronal survival. Mice overexpressing VEGF-B(186) or FLT1 selectively in neurons were protected against the distal neuropathy, whereas exogenous VEGF-B(186), either delivered by gene transfer or as a recombinant factor, was protective by directly affecting sensory neurons and not the surrounding vasculature. Overall, this indicates that VEGF-B, instead of acting as an angiogenic factor, exerts direct neuroprotective effects through FLT1. These findings also suggest a clinically relevant role for VEGF-B in preventing distal neuropathies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21248239      PMCID: PMC3079296          DOI: 10.1096/fj.10-170944

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  36 in total

1.  Erythropoietin for neurologic protection and diabetic neuropathy.

Authors:  Stuart A Lipton
Journal:  N Engl J Med       Date:  2004-06-10       Impact factor: 91.245

2.  Generalized lacZ expression with the ROSA26 Cre reporter strain.

Authors:  P Soriano
Journal:  Nat Genet       Date:  1999-01       Impact factor: 38.330

3.  Favorable effect of VEGF gene transfer on ischemic peripheral neuropathy.

Authors:  P Schratzberger; G Schratzberger; M Silver; C Curry; M Kearney; M Magner; J Alroy; L S Adelman; D H Weinberg; A H Ropper; J M Isner
Journal:  Nat Med       Date:  2000-04       Impact factor: 53.440

Review 4.  Neurotrophins and hyperalgesia.

Authors:  X Q Shu; L M Mendell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

5.  Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration.

Authors:  Yunjuan Sun; Kunlin Jin; Jocelyn T Childs; Lin Xie; Xiao Ou Mao; David A Greenberg
Journal:  Dev Biol       Date:  2005-12-07       Impact factor: 3.582

6.  Intravenous paclitaxel administration in the rat induces a peripheral sensory neuropathy characterized by macrophage infiltration and injury to sensory neurons and their supporting cells.

Authors:  Christopher M Peters; Juan Miguel Jimenez-Andrade; Beth M Jonas; Molly A Sevcik; Nathan J Koewler; Joseph R Ghilardi; Gilbert Y Wong; Patrick W Mantyh
Journal:  Exp Neurol       Date:  2006-09-26       Impact factor: 5.330

7.  Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms.

Authors:  Johanna E Lähteenvuo; Markku T Lähteenvuo; Antti Kivelä; Carolina Rosenlew; Annelie Falkevall; Joakim Klar; Tommi Heikura; Tuomas T Rissanen; Elisa Vähäkangas; Petra Korpisalo; Berndt Enholm; Peter Carmeliet; Kari Alitalo; Ulf Eriksson; Seppo Ylä-Herttuala
Journal:  Circulation       Date:  2009-02-02       Impact factor: 29.690

8.  Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters.

Authors:  Mitsuro Kanda; Shuji Nomoto; Yoko Nishikawa; Hiroaki Sugimoto; Naohito Kanazumi; Shin Takeda; Akimasa Nakao
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

Review 9.  Role and therapeutic potential of VEGF in the nervous system.

Authors:  Carmen Ruiz de Almodovar; Diether Lambrechts; Massimiliano Mazzone; Peter Carmeliet
Journal:  Physiol Rev       Date:  2009-04       Impact factor: 37.312

Review 10.  Peripheral nerve damage associated with administration of taxanes in patients with cancer.

Authors:  Andreas A Argyriou; Martin Koltzenburg; Panagiotis Polychronopoulos; Spiridon Papapetropoulos; Haralabos P Kalofonos
Journal:  Crit Rev Oncol Hematol       Date:  2008-03-07       Impact factor: 6.312

View more
  23 in total

1.  VEGF-B selectively regenerates injured peripheral neurons and restores sensory and trophic functions.

Authors:  Victor H Guaiquil; Zan Pan; Natalia Karagianni; Shima Fukuoka; Gemstonn Alegre; Mark I Rosenblatt
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

2.  Glutamate Neonatal Excitotoxicity Modifies VEGF-A, VEGF-B, VEGFR-1 and VEGFR-2 Protein Expression Profiles During Postnatal Development of the Cerebral Cortex and Hippocampus of Male Rats.

Authors:  Jose Luis Castañeda-Cabral; Carlos Beas-Zarate; Graciela Gudiño-Cabrera; Monica E Ureña-Guerrero
Journal:  J Mol Neurosci       Date:  2017-07-29       Impact factor: 3.444

Review 3.  Molecular pathways linking adipose innervation to insulin action in obesity and diabetes mellitus.

Authors:  Adilson Guilherme; Felipe Henriques; Alexander H Bedard; Michael P Czech
Journal:  Nat Rev Endocrinol       Date:  2019-04       Impact factor: 43.330

Review 4.  Vascular endothelial growth factor signaling in hypoxia and inflammation.

Authors:  S Ramakrishnan; Vidhu Anand; Sabita Roy
Journal:  J Neuroimmune Pharmacol       Date:  2014-03-09       Impact factor: 4.147

Review 5.  Diabetic Microvascular Disease: An Endocrine Society Scientific Statement.

Authors:  Eugene J Barrett; Zhenqi Liu; Mogher Khamaisi; George L King; Ronald Klein; Barbara E K Klein; Timothy M Hughes; Suzanne Craft; Barry I Freedman; Donald W Bowden; Aaron I Vinik; Carolina M Casellini
Journal:  J Clin Endocrinol Metab       Date:  2017-12-01       Impact factor: 5.958

6.  Comparative study of the neurotrophic effects elicited by VEGF-B and GDNF in preclinical in vivo models of Parkinson's disease.

Authors:  X Yue; D J Hariri; B Caballero; S Zhang; M J Bartlett; O Kaut; D W Mount; U Wüllner; S J Sherman; T Falk
Journal:  Neuroscience       Date:  2013-11-27       Impact factor: 3.590

Review 7.  VEGF ligands and receptors: implications in neurodevelopment and neurodegeneration.

Authors:  Peter Carmeliet; Carmen Ruiz de Almodovar; Ruiz de Almodovar Carmen
Journal:  Cell Mol Life Sci       Date:  2013-03-12       Impact factor: 9.261

Review 8.  Vascular endothelial growth factor: a neurovascular target in neurological diseases.

Authors:  Christian Lange; Erik Storkebaum; Carmen Ruiz de Almodóvar; Mieke Dewerchin; Peter Carmeliet
Journal:  Nat Rev Neurol       Date:  2016-07-01       Impact factor: 42.937

9.  Signaling through the vascular endothelial growth factor receptor VEGFR-2 protects hippocampal neurons from mitochondrial dysfunction and oxidative stress.

Authors:  Tianfeng Hao; Patricia Rockwell
Journal:  Free Radic Biol Med       Date:  2013-05-31       Impact factor: 7.376

10.  Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies.

Authors:  Masabumi Shibuya
Journal:  Genes Cancer       Date:  2011-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.